CURE Pharmaceutical expands DEA license to manufacture cannabinoid molecules
CURE Pharmaceutical announced it has broadened its U.S. Drug Enforcement Administration (DEA) license as an authorized manufacturer of Schedule 1 substances to include both cannabis plant extracts and synthetic cannabidiol (CBD).
The Atlantic spotlights Saban Community Clinic’s work with L.A.’s homeless
On one recent February afternoon, the Saban Community Clinic physician assistant Negeen Farmand walked through homeless encampments in Hollywood carrying…